Chirata (Swertia chirayita): Benefits, Dosage, Safety & Evidence

Frequently asked questions

How does Chirata work in the body?

Chirata contains bioactive compounds including amarogentin, swerchirin, swertiamarin, and mangiferin that contribute to its therapeutic effects. These bitter principles stimulate digestive secretions and liver function. The herb exhibits hepatoprotective activity through antioxidant mechanisms, while its antipyretic and antimalarial properties are attributed to its bitter glycosides. Swerchirin has demonstrated blood sugar lowering effects in preclinical studies. Evidence Level: C (preclinical and traditional use).

Does Chirata interact with diabetes medications?

Yes, Chirata may interact with antidiabetic medications. The herb has demonstrated hypoglycemic properties, primarily attributed to the compound swerchirin. When combined with diabetes medications such as insulin, metformin, or sulfonylureas, Chirata may cause additive effects leading to dangerously low blood sugar levels. Diabetic patients should monitor blood glucose closely and consult a healthcare provider before using Chirata. Evidence Level: C.

What is the recommended daily dosage of Chirata powder?

The typical adult dosage of Chirata powder is 1-3 grams daily, taken in divided doses. This herb is extremely bitter, so it is often consumed as a decoction, mixed with honey, or taken in capsule form to improve palatability. Traditional Ayurvedic practitioners may adjust dosages based on individual constitution and condition being treated. Always follow product label instructions or consult a qualified practitioner. Evidence Level: Traditional.

Is Chirata safe to take during pregnancy?

No, Chirata is considered unsafe during pregnancy and should be avoided. The herb's potent bitter compounds and emmenagogue properties may stimulate uterine contractions and potentially lead to miscarriage. There is insufficient safety data for use during breastfeeding, so lactating women should also avoid this herb. Women of childbearing age should use reliable contraception if taking Chirata therapeutically. Evidence Level: C.

What is Chirata used for in traditional medicine?

Chirata has been used in Ayurvedic and traditional medicine for centuries to treat fever, malaria, liver disorders, and for blood purification. Its intensely bitter properties make it valuable for stimulating digestion and liver function. The herb is traditionally employed as an antipyretic to reduce fevers, as a hepatoprotective agent for liver health, and as a blood purifier for skin conditions. Modern research supports some hepatoprotective and antimalarial properties. Evidence Level: C.

What are the side effects of taking Chirata?

Common side effects of Chirata include nausea and stomach upset due to its intensely bitter taste. Some users may experience loss of appetite or digestive discomfort. In diabetic individuals, Chirata may cause hypoglycemia (low blood sugar) due to its glucose-lowering properties. People with gastric ulcers should avoid Chirata as the bitter compounds may aggravate the condition. Starting with lower doses and taking with food may reduce gastrointestinal side effects. Evidence Level: C.

PubMed-compiled information sheet

This sheet was compiled from PubMed (NIH) abstracts using AI assistance. Every factual claim is cited to a real PubMed article (see the source list). It has not yet been human-reviewed — confirm with a healthcare provider before use.

Compiled from 30 PubMed articles · model: gemma4:31b

Summary

Swertia chirayita is a medicinal herb from the Gentianaceae family indigenous to the temperate Himalayas, recognized for its diverse therapeutic potential [PMID:36113678, PMID:26793105].

Background

S. chirayita is a popular medicinal herb indigenous to the temperate Himalayas [PMID:26793105]. It is widely traded as a medicinal substance, often as dried whole plant or extract, and is a significant foreign exchange earner for Nepal [PMID:29960022].

Traditional uses

It has been traditionally used in Ayurveda, Unani, Siddha, Tibetan, and homeopathic systems to treat fever, vomiting, jaundice, digestive disorders, heart diseases, diabetes, malaria, scorpion bites, skin diseases, bronchial asthma, and certain mental disorders [PMID:36113678, PMID:29076426, PMID:26793105, PMID:29960022, PMID:21338178].

Active compounds

The plant contains approximately 123 specialized metabolites, including xanthones, seco-iridoids (such as gentiopicroside, amarogentin, and swertiamarin), terpenoids, alkaloids, and flavonoids [PMID:36113678, PMID:30210007]. Other identified compounds include mangiferin, ursolic acid, and various phenolic constituents [PMID:34381094, PMID:26657265, PMID:38305392].

Mechanism of action

Swertiamarin may ameliorate type 2 diabetes by activating ADRB3/UCP1 thermogenic signals in adipose tissue [PMID:39515102]. Ethanolic extracts have been shown to induce apoptosis in non-small cell lung cancer cells by downregulating the JAK1/STAT3 pathway and elevating ROS levels [PMID:34764752].

Clinical evidence

Evidence DType 2 Diabetes Mellitus

Swertiamarin (100 or 200 mg/kg/day) reduced body weight, blood glucose, and blood lipids in HFD/STZ-induced diabetic mice [PMID:39515102]

Evidence DLiver Disorders / MAFLD

S. chirayita ameliorates metabolic-associated fatty liver disease (MAFLD) in rats by improving the intestinal microenvironment and hepatic lipogenesis [PMID:41802510]; it also demonstrates hepatoprotective and antioxidant effects in CCl4-induced toxicity models [PMID:21549823]

Evidence DCancer

Ethanolic extracts suppressed growth and induced apoptosis in A549 non-small cell lung cancer cells [PMID:34764752]; xanthones from the plant showed cytotoxic potential in breast carcinoma cell lines (MCF-7, MDA-MB-231) and EAC mouse cells [PMID:33107489]

Evidence DDiabetic Neuropathy

Isolated mangiferin from leaves exhibited neuroprotective effects by enhancing antioxidant defense in STZ-induced diabetic rats [PMID:38305392]

Evidence DViral Infections

Certain compounds showed inhibitory activity against Hepatitis B surface antigen (HBsAg) and HBV DNA replication in vitro [PMID:25447162]; crude extract inhibited Vpr expression in HIV-1/HIV-2 related cells [PMID:31076338]

Safety & adverse effects

Analysis of the plant using LIBS and ICP-MS indicated that toxic elements are within safe limits [PMID:39302984].

Drug interactions

A hydro-alcoholic extract of S. chirata showed inhibition potential on hepatic drug metabolizing isozymes CYP3A4 and CYP2D6 [PMID:26657265].

Evidence summary

The current evidence is primarily based on in vitro cell studies, animal models (mice/rats), and literature reviews. There are no human clinical trials (RCTs) provided in the abstracts; therefore, the overall strength of clinical evidence is low (Level D).

PubMed sources

1.PMID: 36113678 (2023) — Swertia chirayita: A comprehensive review on traditional uses, phytochemistry, quality assessment and pharmacology. · Journal of ethnopharmacology
2.PMID: 29076426 (2017) — Swertia chirata: A Comprehensive Review with Recent Advances. · Current pharmaceutical biotechnology
3.PMID: 26793105 (2015) — A Review of Swertia chirayita (Gentianaceae) as a Traditional Medicinal Plant. · Frontiers in pharmacology
4.PMID: 29960022 (2018) — Production from both wild harvest and cultivation: The cross-border Swertia chirayita (Gentianaceae) trade. · Journal of ethnopharmacology
5.PMID: 24992216 (2014) — Metabolic discrimination of Swertia mussotii and Swertia chirayita known as "Zangyinchen" in traditional Tibetan medicine by (1)H NMR-based metabolomics.

Chirata

Sources & Citations

Calculate a safe dose of Chirata

Nectandra rodioei

Jin Qian Cao

Cirsium japonicum

Frequently asked questions

Summary

Background

Traditional uses

Active compounds

Mechanism of action

Clinical evidence

Safety & adverse effects

Drug interactions

Evidence summary

PubMed sources

Government sources

Chirata

Sources & Citations

Calculate a safe dose of Chirata

Related Herbs

Nectandra rodioei

Jin Qian Cao

Cirsium japonicum

Frequently asked questions

Summary

Background

Traditional uses

Active compounds

Mechanism of action

Clinical evidence

Safety & adverse effects

Drug interactions

Evidence summary

PubMed sources

Government sources